Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

Antiarrhythmic agents from Merck & Co.

Feb. 19, 1997

German launch for ACE inhibitor

Feb. 17, 1997

Approval anticipated for TMR using Heart Laser

Feb. 14, 1997

Zeneca describes ET antagonists

Feb. 14, 1997

ICOS' Hu23F2G enters phase II

Feb. 13, 1997

Novel antiarrhythmic agents described by Merck & Co.

Feb. 13, 1997

Novartis launches once-daily hypertension Rx

Feb. 12, 1997

Alexion receives grant for complement inhibitors

Feb. 12, 1997

Sulfonamide derivatives for inhibition of cell adhesion

Feb. 12, 1997

American Home Products describes antiproliferative agents

Feb. 12, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Feb. 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...